StemCell Therapy

CARLSBAD, Calif., June 2, 2020 /PRNewswire/ -- Prescient Metabiomics, a subsidiary of Prescient Medicine Holdings, Inc., announced today a research collaboration with the Harvard Chan Microbiome in Public Health Center (HCMPH Center), a group at Harvard T.H. Chan School of Public Health dedicated to expanding research on the microbiome to improve public health. The aim of the collaboration is to study microbial biomarkers to identify the presence of precancerous adenomas and carcinomas in the colon. The initial collaboration will investigate prevalent gut microbial biomarkers for colorectal cancer (CRC) by analyzing known, recent CRC cases across populations with which the HCMPH Center works and applying cutting-edge statistical and bioinformatic techniques for microbiome meta-analysis.

"The ongoing research collaboration will further enhance diagnostic screening for colon cancer," said Keri Donaldson, M.D, chief executive officer at Prescient Medicine. "Offering a non-invasive alternative to colonoscopies that screen for colorectal adenomas and carcinomas could represent a paradigm shift in CRC screening driven by the microbiome. Therefore, research to better understand the microbiome's role in CRC is needed at this time."

Curtis Huttenhower, Ph.D., professor of computational biology at Harvard Chan School and co-director of the HCMPH Center, said, "The mission of the HCMPH Center is to improve population health via microbiome science, and there are few chronic disease conditions as well-positioned to benefit from microbiome screening as colorectal cancer. It is one of the most common causes of cancer deaths, but also one of the most preventable cancers if detected early. It's exciting to embark on this collaboration to advance the latest science and, I hope, eventually deploy our findings to the clinic."

The past decade has seen a dramatic expansion of research on the human microbiome, including investigation into the role of microbes and microbiota in the gastrointestinal track in the origin and development of CRC. The advancements in this field parallel the preceding decade's growth in personalized genetic medicine, with the microbiome offering opportunities for both therapeutic and diagnostic biomarker discovery.

According to the American Cancer Society, colorectal cancer is the third leading cause of cancer-related deaths in both men and in women. The U.S. spends approximately $14 billion each year for the diagnosis and treatment of CRC with costs largely due to delayed detection. There is a lack of non-invasive screening tests that can accurately detect precancerous polyps as effectively as a colonoscopy, the current standard of care. Screening recommendations currently suggest a colonoscopy for average-risk patients starting at age 45 every 10 years and earlier for high-risk patients, but approximately one in three patients are not in compliance with these recommendations. Research indicates that early detection of precancerous adenomas and carcinomas could lead to significantly better patient outcomes.

About Prescient Metabiomics Prescient Metabiomics LLC, a privately held company and subsidiary of Prescient Medicine Holdings, Inc., is an early stage molecular diagnostics company developing in-vitro diagnostics that leverage breakthroughs in next-generation DNA sequencing, computational systems biology, and human microbiome sciences. To learn more, visit http://www.metabiomics.com.

About Prescient Medicine Holdings Prescient Medicine Holdings, Inc. is a privately held company focused on developing diagnostic tools that advance the precision healthcare movement. Prescient Medicine's mission is to accelerate the development, commercialization and deployment of advanced clinical diagnostics to address the most pressing public health issues in the U.S. Prescient Medicine designs powerful tests and analytic solutions to offer deep predictive insights so doctors and patients have the data they need to make more informed clinical decisions and achieve the best possible patient outcomes. Prescient Medicine technologies include LifeKit® Prevent designed to detect colon cancer and precancerous adenomas and LifeKit® Predict, an in vitro diagnostic test commercialized in partnership with its subsidiary AutoGenomics, used for the identification of patients who may be at risk for opioid dependency. To learn more, visit http://www.prescientmedicine.com.

View original content:http://www.prnewswire.com/news-releases/prescient-metabiomics-and-the-harvard-chan-microbiome-in-public-health-center-collaborate-to-advance-research-in-colon-cancer-screening-301068742.html

SOURCE Prescient Medicine; Prescient Metabiomics

View original post here:
Prescient Metabiomics and the Harvard Chan Microbiome in Public Health Center Collaborate to Advance Research in Colon Cancer Screening - Stockhouse

New York, June 04, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Tumor Genomics Market: Focus on Products, Techniques, Applications, End User, Cancer Type, 14 Countries Data, Industry Insights and Competitive Landscape - Analysis and Forecast, 2019-2028" - https://www.reportlinker.com/p05903975/?utm_source=GNW By Technique: Next Generation Sequencing Technique (NGS), Polymerase Chain Reaction (PCR), Microarray, In-Situ Hybridization (ISH), Immunohistochemistry (ICH), Others (Mass Spectrometry and Flow Cytometry) By Application: Diagnostics and Monitoring, Drug Discovery and Development, and Biomarker Discovery By End User: Academics and Research Organizations, Hospitals and Ambulatory Clinics, Clinical and Diagnostic Laboratories, and Biotechnology and Pharmaceutical Company By Cancer Type: Leukemia, Breast Cancer, Melanoma, Colon Cancer, Lung Cancer, Prostate Cancer, Head and Neck Cancer, and Others (Ovarian, Pancreatic, and Testicular)

Regional Segmentation

North America U.S., Canada Europe Germany, U.K., France, Italy, Spain, Netherlands, Rest-of-Europe Asia-Pacific Japan, China, Australia, India, Rest-of-Asia-Pacific Rest-of-the-World Latin America and Middle East & Africa

Growth Drivers

Rising Government Initiatives and Projects Increasing Incidence of Cancer Increasing Number of Product Approvals and Launches Ever Expanding Application Areas for Genomics Increasing Use of Biomarkers in Cancer Profiling

Market Challenges

High Cost of Genomic Equipment Lack of Unified Framework for Data Integration

Market Opportunities

Growing Prominence for Precision Medicine Increasing Demand for Point-of-Care Diagnostics

Key Companies Profiled

Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, Pacific Biosciences of California, Inc., Myriad Genetics, Inc., and PerkinElmer.

Key Questions Answered: What is tumor genomics? How the different tumor genomic techniques have evolved over the years? What are the major market drivers, challenges, and opportunities in the global tumor genomics market? What was the global tumor genomics market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the market size expected to be in 2028? How is each segment of the global tumor genomics market expected to grow during the forecast period between 2020 to 2028 and what is the revenue expected to be generated by each of the segments by the end of 2028? What are the developmental strategies implemented by the key players to sustain in the competitive market? What is the growth potential of the tumor genomics market in each region, namely, North America, Europe, Asia-Pacific, and the Rest-of-the-World? Which product among the two (assays and kits & instrument) are offered by key players such as Thermo Fisher Scientific, Illumina Inc., Qiagen N.V., and F. Hoffmann-La Roche Ltd.? Which technique is leading the market in 2018 and expected to dominate the market in 2028 and why? Which application and end user type are leading the market in 2019 and are expected to dominate the market in 2028 and why? Which region dominated the global tumor genomics market in 2019 and what are the expected trends from each of the regions in the forecast period 2020-2028?

Market Overview

In order to meet the growing product demand and need, companies are investing in the assays, kits, and instruments used in tumor genomics.Nowadays, large number of kits and reagents are used to test the profiling of mutated genes.

For instance, companies such as Thermo Fisher Scientific, Illumina, Inc., and QIAGEN N.V. have focused on the development of variety of kits for the detection of rare genetic diseases due to cost-effectiveness of the kit as compared to instrument and software, which in turn is causing widespread utilization of kits globally.

The market is also witnessing the launches of various products by receiving FDA approvals such as assay for the study of genes and molecular characterization of DNA. For instance, on, January 16, 2019, QIAGEN received approval from Japanese Pharmaceuticals and Medical Device Agency (PMDA) on therascreen EGFR RGQ PCR Kit which is used as a companion diagnostic for lung cancer patients on treatment with Dacomitinib.

Similarly, several manufacturers are also launching innovative products to expand their offerings in the market. For instance, on November 6, 2019, Thermo Fisher Scientific launched Ion Torrent Genexus System, which is a fully integrated next generation sequencing platform used for profiling of genomes.

The market is favored by multiple factors, which include rising government initiatives, increasing incidence of cancer, therefore increasing the utilization of sequencing to identify the mutant DNA segments, increasing number of product approvals and launches pertaining to genomics market. Moreover, increasing use of biomarkers in cancer profiling is also one of the key driving factors for tumor genomics market.

Government funding is also one of the major growth factors for tumor genomics market, because increasing funding by the government help the research institutes to develop sequencing systems useful for the diagnosis of genetic diseases.Increasing funding shall lead to liquidity of the genomics market and thus companies shall develop various sequencing systems to identify the mutation in the segments of DNA.

All these factors are thus expected to contribute to the market growth during the forecast period.

Within the research report, the market is segmented on the basis of product type, techniques, application, end user, cancer type, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

Major players including QIAGEN N.V., Illumina, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd. Thermo Fisher Scientific, and BGI, among others, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of region, North America is expected to retain a leading position throughout the forecast period 2019-2029, followed by Europe. This is a result of the presence of leading industry players in these regions, and a higher adoption rate of sequencing system to detect the mutation in genes and DNA segments. Moreover, growing research in the field of sequencing technologies including next-generation sequencing technologies (NGS) is one of the drivers that promote the growth of the tumor genomics market.

Countries Covered North America U.S. Canada Europe Germany U.K. France Italy Spain Netherlands Rest-of-Europe Asia-Pacific (APAC) China Japan Australia India Rest-of-Asia-Pacific Rest-of-the-World Latin America Middle East & AfricaRead the full report: https://www.reportlinker.com/p05903975/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
Global Tumor Genomics Market: Focus on Products, Techniques, Applications, End User, Cancer Type, 14 Countries Data, Industry Insights and Competitive...

Have a question about coronavirus, also known as COVID-19?

We will ask the experts.

Send questions to tribdem@tribdem.com.

A reader of The Tribune-Democrat asked:

After much concentration with social distancing and staying at home I inadvertently drank from a soda my granddaughter had been drinking from. She is from a family of four with no apparent symptoms. I am 70 years old with Type 2 diabetes. Is there testing we should have done following this incident or any additional measures? Im nervous that after all my efforts the past 2 1/2 months that I will contract the virus.

The answer:

I congratulate you on all your efforts and safe practices. In my opinion, no testing is indicated unless you develop any symptoms or fever, and no additional measures are needed.

I believe your risk is very low concerning the one incident which you described, and I would not worry. I do recommend that you continue social distancing, good hand washing hygiene, and wearing a face mask. Youre doing a great job!

Dr. David Csikos, chief medical officer, Chan Soon-Shiong Medical Center at Windber.

My employer has required me to havetwo negative tests before returning to work. How long do I have to wait after my first negative test before I can get my second test?

The answer:

The CDC has placed guidelines concerning returning to work after recovery from COVID-19.

These guidelines state that an individual should havetwo consecutive negative results of an FDA-approved COVID-19 molecular assay for detection of SARS-CoV-2 RNA from at least two consecutive respiratory specimens collected greater than 24 hours apart.

Therefore, the least amount of time between testing that can occur is 25 hours.

It is important to point out that an individual must havetwo consecutive negative tests, and results for these tests can take several days to be returned to the individual.

Jill D. Henning, associate professor of biology, University of Pittsburgh at Johnstown.

I am a personal trainer who has had an 89-year-old client request that I come to her home to train her. Besides being a trainer, I also have a part-time job at a regional airport near my home where I handle bagsand check in passengers, as well as cleaning the plane. I am very careful when I work about wearing a mask, gloves, using social distancing and washing my hands. Is it safe for my client if I train her?

The answer:

Im glad that you are using personal protective equipment (PPE) and practicing good hand-washing hygiene. The question of risk exposure for an 89-year-old individual is not insignificant, even though you are taking appropriate precautions.

In the United States, the highest incidence of severe outcomes with COVID-19 were in patients older than 85. Therefore, visitors other than caregivers are not recommended.

Dr. David Csikos, chief medical officer, Chan Soon-Shiong Medical Center at Windber.

I am 75 and have Post Polio Syndrome, chronic bronchitis and shingles. My husband is going back to work at an auto glass manufacturer. How can I isolate in my home? We also have three dogs. Could they carry the virus to me if he gets sick?

The answer:

Self-isolate in a private room and use a private bathroom, if possible. Wear a mask when you enter general living areas. Follow other Pennsylvania Department of Health and CDC recommendations and precautions including good hand-washing hygiene and frequently clean with a sanitizer common surfaces you may both touch.

CDC is aware of a small number of pets worldwide, including cats and dogs, reported to be infected with the virus that causes COVID-19, mostly after close contact with people with COVID-19. Based on the limited information available to date, the risk of animals spreading COVID-19 to people is considered to be low.

Dr. David Csikos, chief medical officer, Chan Soon-Shiong Medical Center at Windber.

I have symptoms of COVID-19 and am scheduled to do my test this morning. It will taketwo days to get results. Is it safe to use my inhaler and nasal spray? And if my test is positive, is it safe to use my inhaler and nasal spray?

The answer:

Im not aware of any inhaler and/or nasal spray contraindications with SARS-CoV-2 (COVID-19). I recommend that you follow-up with your primary care physician.

Dr. David Csikos, chief medical officer, Chan Soon-Shiong Medical Center at Windber.

If the virus has a very short life in/on non-living environments, why is it so important to deep clean spaces that have been vacated for several months?

Wouldnt routine cleaning suffice before the space is occupied again?

The answer:

Cleaning spaces that have been vacant for several months with a deep cleaning is a good idea in general. Many microbes could be present on these surfaces (Staphyloccous and Streptococcus species for example).

There have been news stories circulating that the CDC has changed their guidelines on how SARS CoV-2 spreads. This is untrue. The CDC merely placed the contaminated surfaces under a subcategory stating that the virus does not easily spread via contaminated surfaces. Both the old and new versions of the recommendations state that it is known that the virus can survive on contaminated surfaces for hours to days depending on the surface.

The best way to reduce risk of infection is to wash your hands regularly and clean surfaces with soap and water followed by a disinfectant.

Jill D. Henning, associate professor of biology, University of Pittsburgh at Johnstown.

My husband had COVID-19 symptoms, a sore throat,and because he is 63 years old, we wanted to check to see if he is OK. His results came back positive and he is on a 14-day quarantine. We have now all been tested in the family. So far my youngest daughters results came back negative. Should she move out to be safe?

The answer:

I am assuming the test that all of you received was the genome test. If your husband was positive for the genome, that is indicative of an active infection. This means he is contagious. He needs to quarantine himself and limit the exposure to other family members. It is recommended that high-touch surfaces be cleaned multiple times a day as well.

It is prudent for your daughter (and any other family member who tested negative) to self-isolate in a separate part of the home. Since she is currently living in your home and your husband tested positive, there may have been exposure to SARS CoV-2 since the testing. Testing gives us a snapshot of what is occurring, and since you are all in the same household, there could have been exposure after testing.

If she has a place to go to for 14 days where she is not risking exposure to others, you may want to consider having her go there.

Jill D. Henning, associate professor of biology, University of Pittsburgh at Johnstown.

If I pick up the virus from someone at noon, how soon do I start infecting others?

The answer:

A small number of studies suggest that some people can be contagious during the incubation period, the time between exposure to the virus and the onset of symptoms. The incubation period for SARS-CoV-2 (also known as the COVID-19 virus) is estimated to be between two and 14 days, with a median of five to seven days (possibly longer in children). Greater than 95% of patients develop symptoms within 10-12 days of infection.

Dr. David Csikos, chief medical officer, Chan Soon-Shiong Medical Center at Windber.

My ex and I have shared custody. She just called to say shes in quarantine waiting for COVID-19 test results. I have the children now, but she had them last week before her quarantine.

Do we need to quarantine now until we hear her results? From a concerned father.

The answer:

Yes, self-isolate to your home while you wait for her results. Whoever else lives in your home should also stay at home. Close contacts are people who have been withinsix feet of you for a period of 10 minutes or more. If you or the children develop symptoms, notify your health-care provider for instructions and testing.

Dr. David Csikos, chief medical officer, Chan Soon-Shiong Medical Center at Windber.

How can I keep COVID-19 from spreading in my home once I turn on my whole-house air conditioning? My husband works and I am doing my best to isolate him in his room and a bathroom across the hall.

The answer:

There have been two studies that show the airborne droplets containing SARS-CoV2 can spread farther than six feet when the airflow in a room is increased (either from an air conditioner or a heating system). These systems often draw air in from a room and cool it, sending the cool air throughout the home and the heat outside. This type of system has the potential to circulate the virus in a home if someone is infected.

A study out of the University of Oregon together with the University of California-Davis says the best way to reduce the spread of the virus and still ventilate a room is to open a window. Opening a window in the home will reduce the possible virus concentration by increasing the concentration of air from the outside.

If you cant open the window (allergies, asthma, 95-degree heat) and there is concern that someone in the home is infected (showing symptoms, asymptomatic or exposed), you could block the intake vent in the room(s) that individual is isolating in.

Duct tape can cover the vent and help to reduce the spread of the virus through the home.

Jill D. Henning, associate professor of biology, University of Pittsburgh at Johnstown.

Is there a COVID-19 test my 3-year-old grandson can take that would allow him to stay with us for a day or two if he tests negative? I am 71, and would do anything to see him again.

The answer:

Molecular (Polymerase Chain Reaction PCR) swab test detects RNA from SARS-CoV-2, also known as the COVID-19 virus. If the PCR is positive, the patient is considered infected with the COVID-19 virus and presumed to be contagious.

You mention testing your grandson, but also consider testing the grandparents as well. However, it is important to emphasize that a negative PCR does not exclude COVID-19.

Also, realize that the mean incubation period for COVID-19 is five days, and the range can be two to 14 days. This means that a negative result does not rule out infection.

Dr. David Csikos, chief medical officer, Chan Soon-Shiong Medical Center at Windber.

If a persons antibody IgGand IgM came back positive, are they able to spread the virus because of the IGM result?

The answer:

Testing shows us a snapshot of what is happening with a person andhis/her course of disease. The two types of antibody tests are looking for a particular type of immune response.

When we are exposed to a pathogenic microbe, our immune system has two ways to defeat it.

The first is called the innate response. This response is encoded in our DNA as a human.

It is nearly the same for all of us (with minor differences). This response causes inflammation. It is non-specific and only reacts to each pathogen based on its particular type.

For example, all bacteria are treated the same. It cannot distinguish Streptococcus pyogenes from Staphylococcus aureus. It doesnt distinguish an adenovirus from the Ebola virus.

Most of the time, this innate response kills the invading microbe. When it doesnt, that is when we see symptoms of a disease.

When the innate response cant destroy all of the microbes, then we see the adaptive response.

The adaptive response is specific. This response is different in every individual.

We have a complex immune genetic system to take gene segments and piece them together to create an entirely new gene. Its called somatic recombination. Our germline DNA is pieced together to give us a new never before seen gene to fight a specific pathogen.

That gene is then turned into a protein and made into an antibody for the specific pathogen.

The first antibody made when fighting that response is IgM. If this is found in a test, it indicates the person is in the early stages of the specific response to the virus. IgG is made later, about 14 days into the infection, in the specific response and is often the antibody that allows our immune response to remember the infection (it is made for a few months to years afteran infection).

If a person tests positive for IgG, thatwould suggest theindividual was infected sometime in the past. Ifhe or she is symptomatic, theperson would still be able to transmit the SARS CoV-2 to others, but in most cases the IgG test would be positive after the disease has run its course.

Jill D. Henning, associate professor of biology, University of Pittsburgh at Johnstown.

If a person had COVID-19 in the past, lets say in February, and takes the testagain in May, is the test going to show negative? In other words you could have hadcoronavirus in the past and it would test negative now?

So, the only way to find out if you had it in the past would be the antibody test, correct?

The answer:

Great questions, and it all comes back to testing and more frequent testing. Theres some very recent positive data out of South Korea which Ill discuss below.

Your questions refer to the different types of tests. One test is the molecular swab (Polymerase Chain Reaction PCR), which detects genetic RNA from SARS-CoV-2, also known as the COVID-19 virus. The other test is a blood IgG antibody, which determines if someone was previously infected, or was recently exposed to the virus 10-21 days ago.

If you had COVID-19 infection in February, the PCR swab test would probably be negative now, and the blood IgG antibody test would probably be positive (indicating prior infection). Recent data out of South Korea suggest that if the repeat PCR swab test is positive, that may be detecting dead virus, rather than indicating reinfection. And the positive IgG antibodies may provide some protection.

Because the pandemic is only a few months old, there is no data on long-term immune response.

Read the original:
Experts answer your COVID-19 questions: 'Is there testing we should have done when drinking from my granddaughter's soda or any additional measures?'...

I called Barahonas dorm immediately after I learned the news. There was one person who tested positive, Barahona said, right away. Its here. Barahonas lawyer from the Southern Poverty Law Center, Diego Snchez, had told him, and Barahona had told the other men in his unit. The news was less a revelation than a confirmation of what the men already expected. Barahonas hands were shaking. The officers hadnt given him his diabetes medicine that evening, he said, and he didnt know if he was shaking because his meds were out of whack or because the news about the virus had sent him into a spiral. Im going to try to calm myself down, he said.

The next day, April 10, the federal judge in Barahonas habeas case held a dial-in hearing, in compliance with court social-distancing rules. In court, the warden said he had implemented additional cleaning measures; he wrote in the affidavit that detainees are repeatedly advised by staff to practice social distancing measures in addition to C.D.C. recommended hand-washing procedures. Unfortunately, he noted, detainees often choose not to follow this protocol.

ICEs assistant field-office director for Atlanta wrote in a separate statement that detainees entering facilities were screened and asked whether theyd had contact with anyone with Covid-19. If they said they had, they were separated from other detainees for 14 days. Hand-cleaner dispensers, he said, had been added to the bathrooms, and the facility was routinely cleaned. (Several detainees in the womens unit told me the dispensers were sometimes empty.)

The judge, Clay D. Land, denied the request for the detainees release. The facility, he wrote, could fix the problems and alleviate any constitutional violations without letting these eight people out. This is a terribly hard loss, Snchez, Barahonas lawyer, told me. Nobody can with any honesty say people there are safe.

Immigration detention is an administrative hold, designed to ensure that people facing deportation dont disappear. Because detained immigrants are held neither as consequence of being charged or convicted of a crime nor on orders of a judge, ICE has vast authority to simply release nearly everyone it holds to grant detainees parole. Even detainees with specific past criminal convictions, whom the agency is required, by statute, to detain after their criminal sentence ends, can be released on humanitarian exigencies. The agency can, if it chooses, find other, noncustodial forms of supervision requiring check-ins with officers, say, or forcing detainees to pay a bond, or attaching an electronic monitor to their ankle. Studies show more than 95 percent of immigrants in these release programs comply.

ICE told me that it continues to encourage facilities to follow C.D.C. guidelines and requires detention centers to comply with a set of federal standards, including plans that address the management of communicable diseases. But just last year, a report by the Department of Homeland Securitys inspector general found egregious violations of detention standards, including for medical care. Inspectors hired to perform a review of Irwin County Detention Center in 2017 wrote that the facility was failing to comply with basic standards, noting, among other things, that the medical area and patient examination tables were filthy.

Barahona had heard on TV news reports that most of the people dying of Covid-19 were either old or had health conditions like his. None of the facility workers had told him anything about how to protect himself, he said. My biggest concern is my son. You know, the deepest wish of my heart is to be able to be with him for as long as he needs me.

View post:
Fear, Illness and Death in ICE Detention: How a Protest Grew on the Inside - The New York Times

The current coronavirus pandemic clearly illustrates how dangerous viral infections can become for us. Independent of the present situation, there are people whose bodies are defenseless against infections because their immune systems are unable to combat them - they suffer from immunodeficiency diseases such as ADA-SCID (adenosine deaminase severe combined immunodeficiency) or Wiskott-Aldrich syndrome. Prof. Dr. Alessandro Aiuti, a physician and research scientist based in Milan who works at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) and at the Vita Salute San Raffaele University, is now being honored with the Else Krner Fresenius Prize for Medical Research 2020 for his groundbreaking successes in the development of gene therapies. The award is coupled to 2.5 million euros in prize money.

In the case of the rare immune disorder ADA-SCID, which exclusively afflicts young children and occurs about 15 times a year in Europe, a defective ADA gene within the genome disrupts lymphocyte development, leaving the young patient's body defenseless against infections. "Without effective therapy, the children rarely survive for more than 2 years because any infection can become perilous for them," Aiuti explains. Standard for this therapy is a bone marrow transplantation from a fully matched sibling. However, a suitable donor is available only for a minority of patients. "Meanwhile children with such a condition benefit from the advances we have made in the field of gene therapy. So far we have treated 36 children from 19 countries using the therapy we developed. In more than 80 percent of the cases, the treatment has had such an impact that no enzyme replacement therapy or transplantation is needed. This achievement has been made possible by the extraordinary effort and dedication of SR-Tiget researchers and clinical team throughout 25 years," Aiuti adds. All of the patients are still alive.

For these successes and his other work in the field of gene therapy, Alessandro Aiuti has now been honored with the Else Krner Fresenius Prize for Medical Research 2020 awarded by the Else Krner-Fresenius-Stiftung (EKFS) foundation. At 2.5 million euros, this award is one of the highest endowed prizes for medical research in the world. "Still young by comparison, this year the prize is being awarded for the third time. It honors research scientists for pioneering contributions in the areas of biomedical science. A major percentage of the prize money flows into the prizewinner's research and is supposed to contribute toward achieving further groundbreaking findings and medical breakthroughs in the future as well," emphasizes Prof. Dr. Michael Madeja, scientific director and member of the management board at EKFS.

The decision regarding the prize recipient was made by a ten-member international jury composed of renowned research scientists in the fields of genome editing and gene therapy along with delegates from the Scientific Commission at EKFS. Prof. Dr. Hildegard Bning, chairwoman of the jury and president of the European Society for Gene and Cell Therapy (ESGCT), substantiates the jury's decision: "Alessandro Aiuti is a truly outstanding physician and scientist. His work has decisively contributed to the development and successful treatment of rare, genetically caused disorders such as SCID. Thanks not least of all to the contributions he has made, even patients with other inheritable illnesses can presumably be treated successfully in the future."

After successful clinical trials, the gene therapy developed for ADA-SCID patients was approved as a pharmaceutical remedy in Europe. It is considered to be one of the key findings in the development of gene therapies worldwide. With this treatment certain blood stem cells (CD34+) are taken from the patient, then the cell DNA is modified. The cells are treated outside the body using a viral vector to accomplish this. The correct version of the gene for the ADA enzyme is introduced into the genome of the cells that were collected. The genetically modified cells are returned to the patient's bloodstream via intravenous infusion. A portion of the modified cells subsequently establish themselves in bone marrow again. The patient now has blood stem cells that function properly and produce lymphocytes to defend against infections - presumably on a life-long basis.

Alessandro Aiuti wants to utilize the prize money from EKFS to set the success story forth, to optimize the therapies further and map out the healing mechanisms involved in a better fashion. The scientist sees another major challenge in conveying the acquired knowledge beyond the successful gene therapies from Milan to as many other genetic disorders as possible. Alongside the therapy for ADA-SCID, the San Raffaele Telethon Institute for Gene Therapy has also developed gene therapies for four more hereditary diseases, among them the Wiskott-Aldrich syndrome and metachromatic leukodystrophy (MLD). To this day a total of more than 100 patients from 35 different countries have been treated.

Biography of Alessandro Aiuti

Alessandro Aiuti was born in Rome in 1966 and studied medicine there at Sapienza University. Following a stay at Harvard Medical School in Boston, Massachusetts in the USA, he received his doctorate in Human Biology in 1996 from Sapienza University. Since 1997 he has been active at the San Raffaele Scientific Institute in Milan, where he meanwhile also teaches as a professor at the Vita Salute San Raffaele University. He is furthermore Deputy Director of Clinical Research at the San Raffaele Telethon Institute for Gene Therapy and Head of the Pediatric Immunohematology Unit at San Raffaele Hospital.

Aiuti is the author of numerous and highly acclaimed publications. Over the course of his career he has received a number of prizes from national and international institutions. Aiuti is a member of the board of the European Society of Gene and Cell Therapy, and a member of the EMA Committee for Advanced Therapies since 2019.

The Else Krner Fresenius Prize for Medical Research

The international Else Krner Fresenius Prize for Medical Research came into existence in 2013 on the occasion of the 25th anniversary of Else Krner's death and is awarded in alternating fields of biomedical science. Endowed with 2.5 million euros, the prize is one of the most highly endowed medical research awards in the world. It honors and supports research scientists who have made significant scientific contributions in their fields and whose work can be expected to yield groundbreaking findings and medical breakthroughs in the future as well.

The Else Krner-Fresenius-Stiftung (EKFS) foundation - Advancing research. Helping people.

The Else Krner-Fresenius-Stiftung, a non-profit foundation, is dedicated to the funding of medical research and supports medical/humanitarian projects. The foundation was established in 1983 by entrepreneur Else Krner and appointed as her sole heir. EKFS receives virtually all of its income in dividends from the Fresenius healthcare group, in which the foundation is the majority shareholder. To date, the foundation has funded around 2,000 projects. With a current annual funding volume around 60 million euros the EKFS is one of the largest foundations for medicine in Germany. More information:www.ekfs.de.

The San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget)

Based in Milan, Italy, the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) is a joint venture between the Ospedale San Raffaele and Fondazione Telethon. SR-Tiget was established in 1995 to perform research on gene transfer and cell transplantation and translate its results into clinical applications of gene and cell therapies for different genetic diseases. Over the years, the Institute has given a pioneering contribution to the field with relevant discoveries in vector design, gene transfer strategies, stem cell biology, identity and mechanism of action of innate immune cells. SR-Tiget has also established the resources and framework for translating these advances into novel experimental therapies and has implemented several successful gene therapy clinical trials for inherited immunodeficiencies, blood and storage disorders, which have already treated >115 patients and have led through collaboration with industrial partners to the filing and approval of novel advanced gene therapy medicines.

Fondazione Telethon

Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than EUR 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments. For more information, please visit:www.telethon.it

Issued by news aktuell/ots on behalf of Else Krner-Fresenius-Stiftung

Read the original post:
Groundbreaking Gene Therapies for Hereditary Diseases / Alessandro Aiuti, a physician and research scientist from Milan, receives the Else Krner...

Company Announcement

Copenhagen, Denmark; June 4, 2020 Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for the subcutaneous (SC) formulation of DARZALEX (daratumumab), for the treatment of adult patients with multiple myeloma in all currently approved daratumumab intravenous (IV) formulation indications in frontline and relapsed / refractory settings. The approval follows a Positive Opinion by the CHMP of the European Medicines Agency (EMA) in April 2020. The SC formulation is administered as a fixed-dose over approximately three to five minutes, significantly less time than IV daratumumab, which is given over several hours. Patients currently on daratumumab IV will have the choice to switch to the SC formulation. In August 2012, Genmab granted Janssen Biotech, Inc. (Janssen) an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

We are extremely pleased that patients in Europe with multiple myeloma will now, like patients in the U.S., have the opportunity for treatment with the subcutaneous formulation of daratumumab. With consistent efficacy, and greater convenience for patients and health care providers with dosing time reduced from hours to just minutes and fewer infusion-related reactions, this formulation provides significant benefits for patients, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab

The approval was based on data from two studies: the Phase III non-inferiority COLUMBA (MMY3012) study, which compared the SC formulation of daratumumab to the IV formulation in patients with relapsed or refractory multiple myeloma, and data from the Phase II PLEIADES (MMY2040) study, which is evaluating SC daratumumab in combination with certain standard multiple myeloma regimens. The topline results from the COLUMBA study were announced in February 2019 and subsequently presented in oral sessions at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and the 24th European Hematology Association (EHA) Annual Congress. Updated data of the COLUMBA and the PLEIADES studies were presented during poster sessions at the 61st American Society of Hematology (ASH) Annual Meeting in December 2019.

About the COLUMBA (MMY3012) studyThe Phase III trial (NCT03277105) is a randomized, open-label, parallel assignment study that included 522 adults diagnosed with relapsed and refractory multiple myeloma. Patients were randomized to receive either: SC daratumumab, as 1800 mg daratumumab with rHuPH20 2000 U/mL once weekly in Cycle 1 and 2, every two weeks in Cycles 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study; or 16 mg/kg IV daratumumab once weekly in Cycle 1 and 2, every two weeks in Cycles 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The co-primary endpoints of the study are overall response rate and Maximum trough concentration of daratumumab (Ctrough; defined as the serum pre-dose concentration of daratumumab on Cycle 3 Day 1).

About the PLEIADES (MMY2040) studyThe Phase II trial (NCT03412565) is a non-randomized, open-label, parallel assignment study that includes 265 adults either newly diagnosed or with relapsed or refractory multiple myeloma. Patients with newly diagnosed multiple myeloma are being treated with 1,800 mg SC daratumumab in combination with either bortezomib, lenalidomide and dexamethasone (D-VRd) or bortezomib, melphalan and prednisone (D-VMP). Patients with relapsed or refractory multiple myeloma are being treated with 1,800 mg SC daratumumab plus lenalidomide and dexamethasone (D-Rd). An additional cohort of patients with relapsed and refractory multiple myeloma treated with daratumumab plus carfilzomib and dexamethasone (D-Kd) was subsequently added to the study. The primary endpoint for the D-VMP, D-Kd and D-Rd cohorts is overall response rate. The primary endpoint for the D-VRd cohort is very good partial response or better rate.

About DARZALEX (daratumumab)DARZALEX (daratumumab) intravenous infusion is indicated for the treatment of adult patients in the United States: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI); and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a PI and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma.

DARZALEX is indicated for the treatment of adult patients in Europe via intravenous infusion or subcutaneous administration: in combination with bortezomib, thalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; and as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy2. Daratumumab is the first subcutaneous CD38-directed antibody approved in Europe for the treatment of multiple myeloma. The option to split the first infusion of DARZALEX over two consecutive days has been approved in both Europe and the U.S.

In Japan, DARZALEX intravenous infusion is approved for the treatment of adult patients: in combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma. DARZALEX is the first human CD38 monoclonal antibody to reach the market in the United States, Europe and Japan. For more information, visit http://www.DARZALEX.com.

DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, is approved in the United States for the treatment of adult patients with multiple myeloma: in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.3 DARZALEX FASPRO is the first subcutaneous CD38-directed antibody approved in the U.S. for the treatment of multiple myeloma.

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a persons own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).1,4,5,6,7

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. A comprehensive clinical development program for daratumumab is ongoing, including multiple Phase III studies in smoldering, relapsed and refractory and frontline multiple myeloma settings. Additional studies are ongoing or planned to assess the potential of daratumumab in other malignant and pre-malignant diseases in which CD38 is expressed, such as amyloidosis and T-cell acute lymphocytic leukemia (ALL). Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA for certain indications of multiple myeloma, including as a monotherapy for heavily pretreated multiple myeloma and in combination with certain other therapies for second-line treatment of multiple myeloma.

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of three approved antibodies: DARZALEX (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Arzerra (ofatumumab, under agreement with Novartis AG), for the treatment of certain chronic lymphocytic leukemia indications in the U.S., Japan and certain other territories and TEPEZZA (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. A subcutaneous formulation of daratumumab, DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), has been approved in the U.S. for the treatment of adult patients with certain multiple myeloma indications. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development by Novartis for the treatment of relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody platform for generation of bispecific antibodies, the HexaBody platform, which creates effector function enhanced antibodies, the HexElect platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Contact: Marisol Peron, Corporate Vice President, Communications & Investor Relations T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations: Andrew Carlsen, Senior Director, Investor RelationsT: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmabs most recent financial reports, which are available on http://www.genmab.com and the risk factors included in Genmabs most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at http://www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; DuoBody in combination with the DuoBody logo; HexaBody; HexaBody in combination with the HexaBody logo; DuoHexaBody; HexElect; and UniBody. Arzerra is a trademark of Novartis AG or its affiliates. DARZALEX and DARZALEX FASPRO are trademarks of Janssen Pharmaceutica NV. TEPEZZA is a trademark of Horizon Therapeutics plc.

1 DARZALEX Prescribing information, April 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761036s027lbl.pdf Last accessed April 20202 DARZALEX Summary of Product Characteristics, available at https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex Last accessed October 20193 DARZALEX FASPRO Prescribing information, May 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761145s000lbl.pdf Last accessed May 20204 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848.5Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21.6 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94.7 Jansen, JH et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking.Blood. 2012; 120(21): abstract 2974

Company Announcement no. 24CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122

Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark

Read more from the original source:
Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX (daratumumab) for the Treatment of Patients with...

Professor Wolf Reik has been appointed acting director of the Babraham Institute.

It follows the death of Professor Michael Wakelam, who died from suspected a Covid-19 infection on March 31.

Prof Reik has been the institutes associate director since 2004 and has headed up its epigenetics research programme since 2008.

Prof Peter Rigby, chair of the institutes board of trustees, said: Prof Reik is a world-class scientist, internationally renowned for his work in epigenetics, who has been at the Institute for over 30 years.

The Biotechnology and Biological Sciences Research Council (BBSRC), which funds the institute, approved of the move, he said.

The BBSRC fully support the board's appointment, which will ensure the institute continues to be strongly led, building on the excellent work of Prof Michael Wakelam. I know that Wolf will provide much needed leadership and stability during the uncertain times that we all face, said Prof Rigby.

Prof Reik added: I am really honoured by this appointment; I look forward to working with everyone at the Institute, the campus and with BBSRC.

After Michaels sad death, my primary aim is to bring us back to our labs in a safe and considerate fashion, and to jointly tackle the opportunities and challenges for the science of the Institute going forward strongly into the future.

The study of epigenetics explores the set of instructions that alter how our genome behaves - by regulating gene expression - without changing our underlying DNA code.

Prof Reik explores the role of epigenetics in establishing cell fate and identity during mammalian development and also the process of epigenetic reprogramming.

From the earliest steps in human development, to how stem cells maintain their pluripotency - that is, their ability to change into different cells - Prof Reiks lab is interested in some fundamental questions.

It also explores how the identity of cells is established during the process of differentiation, through which they change into all the different types of cells in our bodies.

Recently, the lab has been studying how the epigenome degrades with age - and whether there are ways of reversing this decay.

New technologies for single cell multi-omics sequencing, which allows unprecedented insights into cell fate changes during development or ageing, have been developed by the lab.

Prof Reik has an interest in collaboration both inside and outside the institute and leads a Wellcome-funded consortium studying cell fate decisions during mouse gastrulation and organ development.

He obtained his MD in 1985 from the University of Hamburg, where he undertook thesis work with Rudolf Jaenisch before completing postdoctoral work with Azim Surani at the Institute of Animal Physiology, which is now the Babraham Institute. During this spell, he became a fellow of the Lister Institute of Preventive Medicine which, in 1987, provided funding for him to start his own independent research group.

He is honorary professor of epigenetics and affiliate faculty at the Stem Cell Institute at the University of Cambridge and associate faculty at the Wellcome Sanger Institute. A member of EMBO and the Academia Europaea, a fellow of the Academy of Medical Sciences and the Royal Society, he has also been a member of funding committees such as UKRI-Medical Research Council, Cancer Research UK and Wellcome Trust.

Read more

How Wolf Reik is unravelling life's other set of instructions at the Babraham Institute

How to build a human: Babraham Institute to unlock secrets of early human development

How Babraham Institute's study of nematode worms can help us understand human ageing

Babraham Institute director Professor Michael Wakelam dies after suspected coronavirus infection

Read the original post:
Professor Wolf Reik appointed acting director of the Babraham Institute - Cambridge Independent

UCLA

Dr. Amar Kishan

FINDINGS

Researchers at the UCLA Jonsson Comprehensive Cancer Center analyzed gene-expression patterns in the most aggressive prostate cancer grade group known as Gleason grade group 5 and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences. The findings may affect how people are treated for the disease.

One subtype, which accounts for about 15% of the grade group 5 cancers, has highly aggressive features and is associated with much worse outcomes than the other subtypes. Another, which makes up about 20% of the tumors, appears to be much less aggressive and may not require intensified and aggressive treatments. Traditionally, all tumors in Gleason grade group 5 have been treated in the same way.

BACKGROUND

Prostate cancer is the leading solid-tumor cancer among men in the United States and a major cause of morbidity globally. While early-stage, localized prostate cancer is curable, current treatments dont always work for everyone. To find out why standard treatment may work for some and not others, the UCLA researchers looked at tumors in the Gleason grade group 5 subset of prostate cancer. These tumors are at the highest risk to fail standard treatment, leading to metastasis and death. The researchers thought that studying the gene expression the unique signature of each cancer cell in these tumors might provide insight into how to make treatments more personalized for each patient.

METHOD

The researchers first analyzed data from more than 2,100 Gleason grade group 5 tumors, looking at how the genetic blueprints differed among the tumors. They identified distinct clusters of subgroups and validated their findings by analyzing an additional cohort of more than 1,900 Gleason grade group 5 prostate cancers.

IMPACT

By using the genetic information from tumors in men with prostate cancer, physicians hope to one day create more personalized treatments based on the actual characteristics of the cancer. This information will help optimize quality of life and avoid overtreating subgroups of men who may not need aggressive treatments.

AUTHORS

The studys lead author is Dr. Amar Kishan, an assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Jonsson Comprehensive Cancer Center. The co-senior authors are Dr. Joanne Weidhaas, a professor of radiation oncology and director of translational research at the Geffen School of Medicine, and Paul Boutros, a professor of urology and human genetics and director of cancer data science for the Jonsson Cancer Center. Boutros is also a member of the UCLA Institute of Urologic Oncology and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at UCLA. Other UCLA authors include David Elashoff, Dr. Rob Reiter and Dr. Matthew Rettig.

JOURNAL

The study was published in the journal European Urology.

FUNDING

The research was funded in part by an award from the American Society for Radiation Oncology and the Prostate Cancer Foundation, the Radiological Society of North America, and the National Institutes of Health.

Original post:
Some types of prostate cancer may not be as aggressive as originally thought - Mirage News

REHOVOT, Israel, June 3, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its participation in the CRISPR-IL consortium. The goal is to develop "Go-Genome", an artificial intelligence (AI) based, end-to-end system for genome-editing to be used in multi-species for pharma, agriculture, and aquaculture. Evogene's CSO, Dr. Eyal Emmanuel will serve as the Chairman of the consortium.

The CRISPR-IL consortium has been approved for 1.5 years by the Israeli Innovation Authority and may be extended to an additional 1.5 years. The consortium's total budget (for the first period) is approximately ILS 36 million (roughly $10 million), partially funded by a grant from the Israeli Innovation Authority. CRISPR-IL participants include leading companies, medical institutions, and academic institutions. Apart from Evogene, key participants include BTG Bio-technology General Israel, Colors Farm, Hazera Seeds, NRGene, Pluristem, Rahan Meristem Ltd., TargetGene; medical institutions: Sheba Medical Center, Schneider Children's Medical Center; and academia: Bar-Ilan University, Ben Gurion University of the Negev, Hebrew University of Jerusalem, IDC Herzliya, Tel-Aviv University and the Weizmann Institute.

CRISPR is a genome-editing technology for detecting and modifying DNA sequences. It is used as a tool to enable precise genetic alterations without the introduction of foreign DNA. The technology enables the development of unique bio-based products and novel therapeutics while reducing the time and cost of development. Current CRISPR-based workflows target precise areas within the DNA, however, these workflows still face several challenges, which prevent more extensive use of this tool, including: (i) accidental off-target modification, (ii) inefficient modifications and (iii) inaccurate measuring tools to ascertain that the modification was effective as intended.

The CRISPR-IL consortium intends to develop an artificial intelligence-based system, "Go-Genome", providing users improved genome-editing workflows. The system aims to provide end-to-end solutions, from user interface to an accurate measurement tool. The system is expected to include the computational design of on-target DNA modification, with minimal accidental, off-target modifications, improve modification efficiency and provide an accurate measuring tool to ensure the desired modification was made. This system intends be designed to be effective in multi-species, including human, plant, and certain animal DNA applicable to market segments in pharma, agriculture and aquaculture.

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of itsGENErator AIsolution (part of Evogene's CPB platform). Evogene'sGENErator AIsolution already includes computational capabilities directing "which"edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve"how"these edits are made.

Dr. Eyal Emmanuel, Chairman of the CRISPR-IL consortium and CSO of Evogene commented: "Our mission is to position Israel as a top technological hub for the use of AI in genome editing. The all-encompassing system the consortium aims to develop, is expected to expand the scope of Evogene's discovery and development offerings for genetic elements, including for its subsidiaries. We believe this is a unique opportunity for applying computational biology and artificial intelligence to genome editing. We are excited to be leading this effort through decoding biology."

Prof. Avraham A. Levy, Chairman of Evogene's Scientific Advisory Board and Dean of the Biochemistry faculty at the Weizmann Institute of Science commented:"The workplan proposed by Evogene within the CRISPIL consortium addresses important gaps in our scientific understanding of the CRISPR technology. Evogene's unique computational analytical tools, together with the data produced by the consortium, have the potential to enable a more effective utilization of genome editing in medicine and agriculture, paving the road for novel products and treatments."

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN.TA) is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology(CPB)platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. Evogene holds a number of subsidiaries utilizing theCPBplatform, for the development ofhuman microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

For more information, please visitwww.evogene.com

Forward Looking Statements:

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning.For example, Evogene is using forward-looking statements in this press release when it discusses the end-to-end solutions provided by the system to be developed and the expansion of the Company's artificial intelligence capabilities and solutions.Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom and those risk factors contained in Evogene's reports filed with the applicable securities authorities. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investor Contact:

US Investor Relations:

Rivka Neufeld

Joseph Green

Investor Relations and Public Relations Manager

Edison Group

E: [emailprotected]

E: [emailprotected]

T: +972-8-931-1940

T: +1 646-653-7030

Laine Yonker

Edison Group

E: [emailprotected]

T: +1 646-653-7035

SOURCE Evogene

Homepage

Read the original post:
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing - PRNewswire

"There are so many unanswered questions, so many puzzles we are yet to solve," she said.

Dr Bart should have been on a plane on Monday, bound for Harvard University and the Brigham and Women's Hospital in Massachusetts for her 10-month Fulbright exchange placement, collaborating with fellow bright minds to unravel the complexities of cardiac genetics.

The Fulbright Program is a highly coveted US foreign exchange scholarship program, aimed at increasing bi-national research collaboration, cultural understanding and the exchange of ideas.

The COVID-19 pandemic has waylaid Dr Bart's travel plans and diverted her attention to the effects of the virus on cardiac patients. But she is continuing her research into the genetic roots of cardiac disease, in particular cardiac amyloidosis, where abnormal protein deposits amyloid fibrils build up in heart tissue, causing heart failure.

Amyloid heart disease used to be a death sentence, Dr Bart said.

"By the time we see patients and diagnose them, it's often too late. We had no treatment we could offer these patients until very recently," she said. "Now that we have those treatments we have a clinical imperative to diagnose early [using genetic testing].

"We are on this cusp of a genetics and genomic revolution where patients can be offered treatment based on their individual genetic make-up," Dr Bart said. "It's hugely exciting".

Being on the cusp of scientific breakthroughs seems like a fitting spot for the expert mountaineer. Dr Bart and her mother, Cheryl Bart, were first mother-daughter team to summit Everest and complete the "Seven Summits" challenge climbing the highest mountains on each continent.

Loading

"I appreciate what it feel like to push your body to the extreme," she said.

"The thing about being in high altitudes, up about 8000 metres, you have to focus on the next step and breath. There's a mindfulness to that focus, and not worrying about the bigger problem. You have a plan in place and you just keep taking that next step."

It's an ethos she brings to her research in the male-dominated field. Women account for just 15 per cent of cardiologists in Australia.

"There is still a huge gender gap, and this is likely affecting outcomes in research," she said. "The fascinating thing about women's hearts is that they behave different to men's. The signs and symptoms are different. Women don't have that thumping elephant-on-the-chest pain. They have more subtle symptoms.

"It's imperative that we have more female specialists and we utilise our different ways of thinking. We need more people to think laterally and collaborate."

Associate Professor Anthony Schembri, chief executive officer at St Vincent's Hospital, described Dr Bart as "a compassionate specialist who cares deeply for each of her patients, at the same time as undertaking research from the bench to the bedside with the aim of achieving long-term improved outcomes in her field of cardiac genetics".

Loading

Victor Chang Cardiac Research Institute executive director Professor Jason Kovacic said Dr Bart was "one of the many inspiring women in science, a trailblazer, pushing the boundaries and paving the way for hopefully more women considering a career as a researcher".

"It is a great honour to be awarded a Fulbright scholarship, and it is a reflection of Dr Bart's dedication to be at the forefront of medical research and ensure that studies are not undertaken in isolation but rather in collaboration with global partners to truly make a difference for patients suffering from heart disease," he said.

Kate Aubusson is Health Editor of The Sydney Morning Herald.

Read more from the original source:
Sydney cardiologist honoured with Fulbright scholarship - Sydney Morning Herald

Global Personalized Cancer Drugs Market: Snapshot

Genetic sequencing has proven that no two cancer cases are absolutely identical, heavily depending on genetic profiles of the patients, which defines their immunity power. But frequently, several promising pipeline drugs fail to reach the market for not being commonly useful for the masses. In this scenario, a small but increasing number of personalized cancer drugs are allowed by the FDA for the treatment of particular mutations. Nearly one third of cancer drugs are prescribed off-label, as it provides help to the patients immediately. These targeted agents are directed at specific molecular feature of the cancer cells and hence produce greater effectiveness with significantly less toxicity.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=118

The global market for personalized cancer drugs market is gaining traction from increased government support for precision-medicine. For example, in June 2016, the U.S. National Cancer Institutes revealed its plans to enroll thousand patients in a trial called NCI-MATCH, which is aimed at matching patients to twenty possible compounds on the basis of their genetic abnormalities. Along the similar lines, The American Society of Clinical Oncology has also announced a registry termed as TAPUR, collecting data on the fate of patients who receive personalized cancer drugs off-label.

Another factor driving the global personalized cancer drugs market is the falling cost of genetic sequencing, which is enabling the quick approval of drugs for off-label clinical trials on patients in need across the world.

Personalized Cancer Drugs Market: Overview

Personalized drugs, or customized drugs, are tailored to suit the needs of individual patients. Earlier, various patients suffering from the same type of disease were given the similar treatment plan. However, it became evident to physicians that a particular treatment worked differently for different patients, mainly owing to a varied genetic makeup. The concept of personalized medicine is based on the analysis of etiology of disease in individual patients and offers treatment that is more efficient, predictable, and precise.

Cancer is a common chronic disease and a major cause of fatality around the globe. The development of personalized cancer drugs has gained pace as they have relatively fewer side effects compared to standard drugs. Personalized cancer drugs target a specific protein or gene responsible for the growth and survival of a cancer type.

Personalized Cancer Drugs Market: Trends and Opportunities

The personalized cancer drugs market is primarily fueled by the rising prevalence of various cancer types such as lung cancer, breast cancer, prostate cancer, melanoma and leukemia, and colorectal cancer. According to the Surveillance, Epidemiology, and End Results Program sponsored by the National Cancer Institute (NCI), an estimated 13,397,159 people in the United States were affected with various cancer types in 2011. Moreover, in 2014, around 1,666,540 new cancer cases were diagnosed in the country, with nearly 585,720 deaths resulting from cancer. The personalized cancer drugs market is also driven by several advantages associated with this new treatment therapy and ongoing developments in the field of genetic science.

On the flip side, high cost associated with the genetic testing of patients and tumor samples may serve as a growth restraint on the market for personalized cancer drugs. In addition to this, the lack of insurance plans to cover these tests in developing nations of Asia Pacific and Rest of the World hampers the market to some extent. This can be attributed to low per capita income and poor reimbursement scenario.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=118

Personalized Cancer Drugs Market: Geographical Assessment

From a geographical perspective, the personalized cancer drugs market has been broadly segmented into Europe, Asia Pacific, North America, and Rest of the World (RoW). The market for personalized cancer drugs is led by North America. The chief factors responsible for the regions lead position are aggressive research and development activities, technical advancements, higher affordability for expensive treatments and therapies, and greater healthcare awareness. Europe is also a key market for personalized cancer drugs owing to significant funding from several governments and the growing penetration by U.S.-based companies.

Asia Pacific holds immense promise for players in the personalized cancer drugs market, powered mainly by Japan. The regional market is likely to be fueled by the presence of a large pool of cancer patients and improving healthcare infrastructure. The growth of the APAC personalized cancer market can also be attributed to the rapidly evolving medical tourism industry. In the RoW segment, Mexico, Brazil, Russia, and South Africa represent potential markets.

Personalized Cancer Drugs Market: Competitive Landscape

Some of the key players competing in the personalized cancer drugs market are F. Hoffmann-La Roche Ltd., Pfizer Ltd., Cell Therapeutics, Inc., H3 Biomedicine, Inc., bioTheranostics, GlaxoSmithKline, and Abbott Laboratories. Zelboraf (vemurafenib) by F. Hoffmann-La Roche Ltd. and Xalkori (crizotinib) by Pfizer Ltd. are some notable targeted drugs for the treatment of cancer.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/personalized-cancer-drugs-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

The rest is here:
Personalized Cancer Drugs Market Key Companies and Analysis Top Trends by 2025 - Cole of Duty

THE ultimate warrior would be unable feel fear or pain, capable of running at Olympic speeds, and even immune to modern weapons.

Their existence was once only possible in the realm of science fiction but a new worldwide arms race is pitting nation states against each other to be the first to successfully create real genetically modified super soldiers.

Militaries have a long history of using powerful drugs to temporarily turn their troops into transcendant Terminator-style killers.

Nazis took methamphetamine or "crystal meth" during the Second World War to stay alert and awake for superhuman stretches of time.

And even the British military bought thousands of Modafinil pills which boost brain-power ahead of the Iraq War.

In China, it is reasonable to assume that they are enhancing their battlefield soldiers on all these fronts.

But with advances in technology, it could now be possible to alter soldiers' DNA to give them godlike powers all the time, from Herculean strength to lizard-like limb regeneration.

GM technology is proven with plants, it could absolutely be applied to the person, said Professor John Louth, an expert at defence think tank Rusi.

In China, it is reasonable to assume that they are enhancing their battlefield soldiers on all these fronts.

China's armed forces are the largest in the world, consisting of a staggering 2.2million personnel.

This year alone, Beijing is spending $178.16billion on its defence budget.

But as the country's international relations flare up, they could be looking to be the first army to have genetically modified super soldiers to get ahead of adversaries.

5

These combatants would be stronger, faster and even smarter than their battlefield opponents.

Their DNA could also be adapted to help them recover more quickly from injuries or give them superior hearing and night vision.

The threat is obvious and real. Chinese money could be stealing a march on western armed forces and that is deeply concerning," Prof Louth said.

Concerns about China's super soldier plans came after a Chinese scientist, He Jiankui, claimed to have successfully created genetically modified babies using gene editing technology.

5

5

China jailed Dr Jiankui for illegal medical practices over his claims to have made three babies immune to HIV.

But it's now suspected that Chinese military chiefs are backing trials into human gene editing.

But they're not alone.

The US has also conducted some strange super-soldier research projects.

They've already publicly unveiled a 5million Iron Man-style exoskeleton which gives fighters incredible muscle-power.

5

And the Defense Advanced Research Projects Agency (DARPA) developed ways for warfighters to scale walls by studying the skin of geckos.

Novelist Simon Conway, who was granted behind-the-scenes access at the secretive Pentagon agency, revealed a string of other super soldier programmes underway there in 2012.

He claims scientists were working on gene modification that would allow soldiers' bodies to convert fat into energy more efficiently, allowing them to go days without eating.

What is gene editing?

"It's all about improving the efficiency of energy creation in the body," Conway told the Sunday Express.

"Soldiers would be able to run at Olympic speeds, carry large weights and go without sleep and without food."

But the US isn't just looking at how biotechnology can give their soldiers the upper-hand on the battlefield.

They're also carrying out research into medical regeneration, allowing severely injured soldiers who've lost limbs or suffered extensive burns to heal organically.

This is already a reality in the animal kingdom, where lizards can regrow amputated tails and salamanders can restore entire severed limbs.

"We would like it to be as restorative as possible, resist infection and be durable," said Army Lt. Col. David Saunders, extremity repair product manager for the U.S. Army Medical Materiel Development Activity.

"[There are] many wonderful things emerging in the field of regenerative medicine to restore form and function to our wounded warfighters."

As recently as January 2020, the US military was unveiling incredible advances in warzone genetics.

5

Army researchers developed a gene therapy that allowed mice to create proteins that would protect them against nerve agents deadly chemical weapons that attack the nervous system, like the Russian Novichok used in the Salisbury poisonings in 2018.

The same gene therapy given to the mice that made them chemical weapon-proof could theoretically be used in soldiers entering hazardous environments.

Before Russia's nerve agents were used with terrible effect, president Vladimir Putin had warned of an even more terrifying weapon.

Speaking at a 2017 youth festival in Sochi, Putin spoke openly about the destructive possible consequences of gene-editing.

"A man has the opportunity to get into the genetic code created by either nature, or as religious people would say, by the God," he said, The Express reports.

"He can be a genius mathematician, a brilliant musician or a soldier, a man who can fight without fear, compassion, regret or pain.

"As you understand, humanity can enter, and most likely it will in the near future, a very difficult and very responsible period of its existence.

"What I have just described might be worse than a nuclear bomb."

But instead of this being something in the "near future", Russia is already factoring genetics into its military strategy.

Alexander Sergeyev, the head of the country's Academy of Sciences, revealed the armed forces were researching "genetic passports" in 2019, Forbes reports.

The passports would predict a soldier's "resistance to stress, ability to perform physical and mental operations under the conditions of this stress, and so on."

Sergeyev added that they could be used to sort which branch of the armed forces personnel would be sent to.

"There are already serious developments in this area," he said.

"It is about understanding at the genetic level who is more prone to, for example, to service in the fleet, who may be more prepared to become a paratrooper or a tankman."

What I have just described might be worse than a nuclear bomb.

And unlike other world leaders, Putin has a very close interest in genetic editing.

That's because his eldest daughter, Maria Vorontsova, is a scientist who specialises in genetic engineering and acts as his adviser on the matter.

In 2018, before He Jiankui revealed his HIV-immune babies in China, Putin had already allotted $2billion for genetic research, Bloomberg reports.

INK AGAINBored tattoo lovers do their OWN DIY inkings - and even Kaia Gerber's a fan

Comment

Leo McKinstryTories must keep a tight grip on spending or risk a return to misery of 1970s

PAIN IN SPAINInside Costa Del Sol's bloody gang wars as thugs dish out 'medieval' torture

WHO CARES WINSInside wobble rooms where nurses & doctors go to escape Covid trauma

Exclusive

CYBER CRIMEWe're 'armchair detectives' investigating grim cold cases from our own homes

He even put Vorontsova in charge of the 30-person panel overseeing the experiments.

Watching world superpowers will undoubtedly be paying attention to Putin's potential to weaponise the research.

After all, as Putin says, genetic editing is an area of science which will "determine the future of the whole world".

Read more:
Inside the super-soldier arms race to create genetically modified killing machines unable to feel pain or fe - The Sun

The National Human Genome Research Institute definesgenomic medicine asan emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., fordiagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use. Genomic medicine is a type of precision medicine in which genomics, epigenomics and other related data is used to accurately aid in individual disease diagnosis. Genomic medicine has novel applications in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.Genomic medicine paves way for personalized medicine into clinics and has immense potential to reach the physicians and patients. Genomic medicine has been used for advanced sequencing in cancer pharmacogenomics, rare disorder diagnosis and for tracking of outbreaks of infectious diseases.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/11323

Genomic Medicine Market: Drivers & Restraints

Backed by government investments in precision medicine initiatives such as a multimillion dollar investment by President Obama in January 2015 which aims to improve how to treat and prevent a disease by laying emphasis on its genetic makeup is expected to boost the market growth. Clinical validity and utility of genomic medicine tests is a major issue witnessed in the global market. Also, lack of awareness among healthcare professionals, sluggish adoption of genome medicine, fluctuating regulatory landscape are the factors which could hamper growth of the global genomic medicine market.

Genomic Medicine Market: Segmentation

The global genomic medicine market is classified on the basis of application type, end use and region.

Based on application, the global genomic medicine market is segmented into the following:

Based on end use, the global genomic medicine market is segmented into the following:

Genomic Medicine Market: Overview

Genomic medicine is gaining momentum with expanding applications ranging from risk assessment and diagnosis in healthy individuals to genome-based treatment for patients with complicated disorders. Oncology is a major application of genomics medicine during cancer screening process as diagnostics for genetic and genomic markers. Oncology segment is expected to account for a major share in the global genomic medicine market. Genomic medicine is increasingly being used not only for research purpose but also in clinical applications. In clinical applications, genomic medicine will potentially enhance patient care.

Genomic Medicine Market: Region wise Overview

Geographically, global Genomic Medicine market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, Middle East and Africa (MEA). Owing to the presence of large number of academic as well as research institutions in the U.S. which are working on genomic medicine to discover next-generation genomic medicines, North America region is projected to lead the global genomic market in terms of value during the forecast period. Also, the presence of several universities offering educational programs coupled with opportunities in scientific research of genomic medicine in the North America and Europe is expected to have positive impact on the regional markets. The genomic medicine concept still in its nascent stage is yet to receive an impetus from the emerging market which are anticipated to hold smaller shares in the global market.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/11323

Genomic Medicine Market: Key Players

The key research institutes in global genomic medicine market are BioMed Central Ltd., Cleveland Clinic, The University of Texas MD Anderson Cancer Center, The Manchester Centre for Genomic Medicine, Center for Genomic Medicine to name a few. The focus of the top players will be on the identification of effective drug candidates particularly in cancer treatment based on the molecular structure of tumors.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, accessories and applications.

Link:
Growth in Sales of Genomic Medicine Market to be Largely Driven by Rising Consumer Adoption - Cole of Duty

Precision medicine (PM) is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. Personalized nanomedicine involving individualized drug selection and dosage profiling in combination with clinical and molecular biomarkers can ensure the maximal efficacy and safety of the treatment. The major hindrance toward the development of such therapies is the handling of the Big Data, to keep the databases updated. Robust automated data mining tools are being developed to extract information regarding genes, variations, and their association with diseases. Phenotyping, an integral part of PM, is aimed at translating the data generated at cellular and molecular levels into clinically relevant information.Precision Medicine Moves Care from Population-Based Protocols to Truly Individualized Medicine as President of the US announced the Precision Medicine Initiative in his 2015 State of the Union address. Under the initiative, medical care would transition from a one-size-fits-all approach to an individualized approach, in which data on each patients genomic makeup, environment, and lifestyle (the exposome) helps medical professionals tailor treatment and prevention strategies. To achieve the Precision Medicine Initiative mission statement, to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care, researchers and clinicians need vast and varied amounts of data and the technology to ensure that data is widely accessible and usable.

Browse Complete Report with TOC https://univdatos.com/report/precision-medicine-market-current-analysis-and-forecast-2020-2026

Insights Presented in the Report

Based on technology type, the market is fragmented into big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.Recent technological and analytical advances in genomics, have now made it possible to rapidly identify and interpret the genetic variation underlying a single patients disease, thereby providing a window into patient-specific mechanisms that cause or contribute to disease, which could ultimately enable the precise targeting of these mechanisms

Based on the market segment by application type, the market is segmented into oncology, respiratory diseases, central nervous system disorders, immunology, genetic diseases and others. With the advent of precision medicine, cancer treatment is moving from a paradigm in which treatment decision isprimarily based on tumor location and histology followed by molecular information to a new paradigm whereby treatment decisions will be primarily based on molecular information followed by histology and tumor location

Based on the market segment by end-user, the market is fragmented into hospitals & clinics, pharmaceuticals, diagnostic companies, Healthcare-IT firms and others. The precision medicine suppliers that understand technology and the goals of value-based healthcare can create value in the precision medicine value-chain by offering value-based solutions and platforms to interpret and connect data points. There are a number of technology companies who work in the field of precision medicine and more will be founded in the years to come

For better understanding on the market dynamics of Precision Medicine market, detailed analysis was conducted for different countries in the region including North America (United States, Canada, Mexico and Rest of North America), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, Australia, India and Rest of APAC), and Rest of World

Some of the major players operating in the market includeHoffmann-La Roche, Medtronic, Qiagen, Illumina, Abbott Laboratories, GE Healthcare, NanoString Technologies, bioMrieux SA, Danaher Corporation, and AstraZeneca

Request for Sample of the report https://univdatos.com/request_form/form/286

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends and opportunities prevailing in the industry.

Examination of industry attractiveness with the help of Porters Five Forces analysis

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Feel free to contact us for any queries https://univdatos.com/request_form/form/286

Customization Options:

Precision MedicineMarket can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

About us:

UnivDatos Market Insights (UMI), is a passionate market research firm and a subsidiary of Universal Data Solutions. We believe in delivering insights through Market Intelligence Reports, Customized Business Research, and Primary Research. We are a diverse group of some of the most talented people in the research landscape, who with their collective experience, help us drive our machine and creatively solve every business challenge of millennial organizations. Our team comprises of accomplished professionals from leading consulting environments and serve some of the significant Fortune 500 companies around the world.

Contact us:

UnivDatos Market Insights (UMI)

Email: [emailprotected]

Web: https://univdatos.com

Ph: +91 7838604911

Link:
COVID-19 Impact on Precision Medicine Market: Outlook, Growth, Key Driving Players and Industry Analysis Report 2026 - Cole of Duty

Authors: Bamba; Golden Jackson, PhD; Cristina Hernandez; Delroy Daley; and David Rodda, PhD, Associate Professor of Molecular Cell Biology of the AUC School of Medicine.

Hey friends! Its Bamba here and I cant wait to talk to you about some exciting, cool science today! This self-quarantine gave me a lot of time to think and I wondered, How do humans get the colour of their eyes?

Genetic expert, Dr. Rodda of AUC School of Medicine helped me explore this eye-opening mystery get it? Eye-opening? Ha-ha! Well, the answer to that question is in your genes not the ones you wear!

Did you know that humans are born with pre-made instructions? Yes, thats right! Humans and all other organisms have DNA that holds instructions, like a users manual, for how our bodies grow and develop!

DNA is a tiny, little molecule found inside every cell of our bodies and the instructions in the DNA are called genes. Genes determine how tall you will be, the texture of your hair, the colour of your eyes, and much more.

You have two copies of all your genes, one copy you received from your mother, the other copy you received from your father. Next, your genes in DNA are wrapped up in chromosomes the bundle that packages your genes together.

So, how do your genes determine your eye colour? According to experts, there are eight genes that control the colour of your eyes. You have two sets of these genes that came from each of your parents. Sometimes you might receive different versions of these genes from your parents.

For example, you may receive a gene that makes blue eyes from your father, and a gene that makes brown eyes from your mother. So, what colour would your eyes be then? That depends on what scientists call the dominance of the genes.

With eye colour, brown eyes are dominant, so if you have genes for both brown and blue eyes, your eyes will be brown. You can only have blue eyes if you don't have a gene for brown eyes. What about people who have green or hazel eyes? A different gene makes those colours, but still brown eyes are dominant, so just like with blue eyes, a person can only have green or hazel eyes if they dont have a gene for brown eyes.

Did you know you can have different coloured eyes than your parents? If a child is born to parents who both have brown eyes, there is a greater chance of their child having brown eyes, but there is also a chance their child can have blue or green eyes. The chart shows the likelihood (chance) of a child having eyes of a particular colour based on the colour of their parents eyes.

Did you know the amount of melanin you have in your eyes is another factor that helps determine eye colour? Melanin is a pigment that people have that normally determines how dark or light their features are. For example, a darker skinned person has more melanin in their skin than a lighter skinned person.

This is also true in eye colour. If your melanin gene is turned on high, then your eyes will be darker and browner. The less melanin in your eyes, then the lighter your eyes will be, resulting in green or blue eyes. No matter the size, shape, or shade of your skin, the colour of your eyes is based on genetics and chance!

Well there you have it! Another fun science exploration with you guys! Until next time, stay safe!

~Bamba out!

View post:
Why do you have that eye colour?: Exploring Health with Bamba - The Daily Herald

"Diabetic Peripheral Neuropathy Market"

According to DelveInsight, the Diabetic Peripheral Neuropathy Market in 7MM was found to be approximately USD 2,275.52 Million in 2017 and is set to increase by 2030.

Geography Covered

Study Period: 20172030

Diabetic Peripheral Neuropathy Disease Overview

Diabetic peripheral neuropathy (DPN) also known Distal symmetric polyneuropathy (DSPN) is defined as the symptoms and/or signs of peripheral nerve dysfunction and nerve damage in diabetic patients after the exclusion of other causes. It is a predominantly sensory neuropathy with autonomic nervous system involvement, although there are often motor features with advancing disease.

As per the American Diabetes Association, most common among diabetic neuropathies are chronic DPN, accounting for about 75% of the diabetic neuropathies.

Diabetic Peripheral Neuropathy Epidemiology

DelveInsights estimations suggests the total prevalent cases of Diabetic Peripheral Neuropathy in the 7MM was found to be approximately 25,332,829 in 2017.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM, Gender-Specific Prevalence of Diabetic Peripheral Neuropathy in 7MM, Total Diagnosed Prevalence of Painful Diabetic Peripheral Neuropathy in 7MM), scenario of Total Diagnosed Prevalence of Diabetic Peripheral Neuropathy in 7MM in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 20172030.

Visit to know more about the report: https://www.delveinsight.com/report-store/diabetic-peripheral-neuropathy-market

Diabetic Peripheral Neuropathy Market: Treatment and Emerging Therapies

The rising global burden of diabetes is spurring an increase in the prevalence of diabetic neuropathy and neuropathic pain. At present, there are no FDA-approved pathogenetic therapies for DPN and the efficacy of treatments for painful DPN is limited.

The management of pain remains the key aspect of symptom treatment for DPN. The current medications fall into categories, such as antidepressants, anticonvulsants, topical agents and opioids. Antidepressants are further divided into selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCA) group.

Treatments currently approved by both FDA and EMA for pain associated with DPN includepregabalin, duloxetine, and extended-release tapentadol and capsaicin 8% patch. However, no treatments have been approved for the prevention or reversal of DPN.

According to DelveInsight, the Diabetic Peripheral Neuropathy Market in 7MM was found to be approximately USD 2,275.52 Million in 2017 and is set to increase by 2030.

Request for sample pages: https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market

Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Ebranopadol (Grnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies.

The key pharma players working in Diabetic Peripheral Neuropathy Market are:

1. Helixmith,

2. Aptinyx

3. WinSanTor, Inc

4. Regenacy Pharmacuticals

5. Ichnos Science

6. Novaremed

7. Grnenthal GmbH

8. Glenmark Pharmaceuticals

9. AstraZeneca

10. Angelini

And many others

Diabetic Peripheral Neuropathy Report Insights

Table of Contents

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy Market Overview at a Glance

4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology

5. Diabetic Peripheral Neuropathy Disease Background and Overview

6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

7. Diabetic Peripheral Neuropathy Treatment and Management

8. Diabetic Peripheral Neuropathy Unmet needs

9. Diabetic Peripheral Neuropathy Marketed Drugs

10. Diabetic Peripheral Neuropathy Emerging drugs

11. Diabetic Peripheral Neuropathy Market Size

12. Diabetic Peripheral Neuropathy Reimbursement policies

13. Diabetic Peripheral Neuropathy Market Drivers

14. Diabetic Peripheral Neuropathy Market Barriers

15. SWOT Analysis

16. KOL Views

17. Diabetic Peripheral Neuropathy Case Report

18. A Case Report of Diabetic Peripheral Neuropathy

19. Bibliography

20. Appendix

21. Diabetic Peripheral Neuropathy Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Browse through our vast repository

Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Vinita Rakheja Email: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: http://www.delveinsight.com/

See more here:
Diabetic Peripheral Neuropathy Market is Anticipated to Increase Owing to a Rich and Robust Pipeline - Press Release - Digital Journal

LAS VEGAS, June 2, 2020 /PRNewswire/ -- Diabetic Peripheral Neuropathy Market will increase because of the rising global burden of diabetes that is driving prevalence of diabetic neuropathy, advancement in early diagnosis as well as launch of the promising therapies which will positively impact DPN market.

DelveInsight added a new report titled "Diabetic Peripheral Neuropathy MarketInsights, Epidemiology, and Market Forecast-2030" to its portfolio.

Key Highlights from Diabetic Peripheral Neuropathy Market report are:

Request for sample pages to know more onDiabetic Peripheral Neuropathy Epidemiology and Market Forecast

Diabetic Peripheral Neuropathy is a painful condition that is caused by nerve damage from diabetes. It is a common prevalent complication in neurological damage of Type 1 and Type 2 diabetes.

There is a huge patient population pool affected by the disease; the Diabetic Peripheral Neuropathy market report covers the disease epidemiology that is segmented into Total Diagnosed Prevalent Cases of DPN, Total Prevalent Cases of Painful DPN and Gender-specific Prevalent cases of DPN in the 7MM from 2017 to 2030.

The total Painful Diabetic Peripheral Neuropathy Prevalent Cases were 3,857,945 in the United States in 2020. Also, females are more affected by the disease as compared to males for Diabetic Peripheral NeuropathyPrevalent in the US in 2020.

Click here to know more onDiabetic Peripheral Neuropathypipeline

Among the 7MM, the US accounts for 58% of the overall market size of DPN. Among the EU-5 countries, Germany accounts for the highest market size for DPN. Diabetic Peripheral Neuropathy market has a diverse pipeline with several promising therapies. Also, Gene therapy has been developed for DPN pain management. Of the emerging therapies, the most anticipated product to get launched is VM202 Apart from this, other products include VM202 (Helixmith), NYX-2925 (Aptinyx), WST-057 (4% pirenzepine) (WinSanTor, Inc.), Ricolinostat (Regenacy Pharmacuticals), NRD.E1 (Novaremed Ltd.), Cebranopadol (Grnenthal GmbH), GRC 17356 (Glenmark Pharmaceuticals), and others are also expected to enter the market by 2030 as effective therapies. The potential launch of these emerging drugs will aid in overall market growth. There are a couple of market drivers which will be driving the market. One such factor will be an early diagnosis of the DPN because of the advancements happening in the DPN diagnostic approaches. As the patient pool for diabetic peripheral neuropathy is quite large, and there is no treatment for reversal of disease, this indication withholds a plethora of opportunities for drug development companies. No doubt that the clinical pipeline contains a large number of drugs; however, previously multiple clinical trial failures gave a setback and limited the research and development in the DPN domain. So far it has been clear that path traversed is not easy in DPN research as the long-term clinical trials and low success rate in meeting the clinical endpoints may become threats for the investors to fund further.

There aremany key players robustly involved in developing potential drugs and they are a ray of hopefor DPN patients such as:1. VM2022. NYX-29253. WST-0574. Ricolinostat5. ISC 175366. NRD135S.E17. Cebranopadol8. GRC 173569. MEDI735210. Trazodone/GabapentinAnd many others

The key players involved in Diabetic Peripheral Neuropathy market are:1. Helixmith2. Aptinyx3. WinSanTor, Inc4. Regenacy Pharmacuticals5. Ichnos Science6. Novaremed7. Grnenthal GmbH8. Glenmark Pharmaceuticals9. AstraZeneca10. AngeliniAnd many others

The reasons for buying Diabetic Peripheral Neuropathy market report:

Table of contents

1. Key Insights

2. Executive summary

3. Diabetic Peripheral Neuropathy Market Overview at a Glance

4. Diabetic Peripheral Neuropathy Epidemiology and Market Methodology

5. Diabetic Peripheral Neuropathy Disease Background and Overview

6. Diabetic Peripheral Neuropathy Epidemiology and Patient Population

6.1. Key Findings

6.2. Total Diagnosed Prevalent cases of Diabetic Peripheral Neuropathy in 7MM

6.3. United States

6.4. EU5

6.5. Germany

6.6. France

6.7. Italy

6.8. Spain

6.9. United Kingdom

6.10. Japan

7. Diabetic Peripheral Neuropathy Treatment and Management

8. Diabetic Peripheral Neuropathy Unmet need

9. Diabetic Peripheral Neuropathy Marketed Drugs

9.1. Key cross competition

9.2. Qutenza: Grnenthal

9.3. Tarlige: Daiichi Sankyo

10. Diabetic Peripheral Neuropathy Emerging drugs

10.1. Key cross competition

10.2. VM202: Helixmith

10.3. NYX-2925: Aptinyx

10.4. WST-057: WinSanTor

10.5. Ricolinostat: Regenacy Pharmaceuticals

10.6. Cebranopadol: Grnenthal

10.7. ISC 17536: Ichnos Science

10.8. NRD135S.E1: Novaremed

10.9. MEDI7352: AstraZeneca

10.10. Trazodone/Gabapentin: Angelini

11. Diabetic Peripheral Neuropathy Market Size

11.1. Key Findings

11.2. Total Market Size of Painful Diabetic Peripheral Neuropathy in 7MM

11.3. Diabetic Peripheral Neuropathy Market Outlook: 7 MM

11.4. United States

11.5. EU5

11.6. Germany

11.7. France

11.8. Italy

11.9. Spain

11.10. United Kingdom

11.11. Japan

12. Diabetic Peripheral Neuropathy Reimbursement policies

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. KOL Views

17. Diabetic Peripheral Neuropathy Case Report

18. A Case Report of Diabetic Peripheral Neuropathy

19. Bibliography

20. Appendix

21. Diabetic Peripheral Neuropathy Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Request a WebEx Demo to get a walk-through of the Diabetic Peripheral Neuropathy Market Report:https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market

Related Reports:

Diabetic Peripheral Neuropathy Epidemiology Forecast-2030 report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in the 7 MM.

Diabetic Peripheral Neuropathy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Diabetic Peripheral Neuropathy market.

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.

Contact us:

Shruti Thakur[emailprotected]+91-9650213330DelveInsight

SOURCE DelveInsight Business Research, LLP

More here:
Diabetic Peripheral Neuropathy Market is Expected to Increase with a CAGR of 12% for the Study Period of 2017-2030: DelveInsight - PRNewswire

Auditory neuropathy was first described in 1996 by Arnold Starr, MD, and colleagues as a hearing impairment that, by behavioral and physiological testing, were compatible with a disorder of the auditory portion of the eighth cranial nerve.1 Since then, research has found notable hallmarks of normal outer hair cell function in the presence of severely abnormal or absent auditory brainstem evoked potentials. When measurable, speech discrimination scores are proportionally lower than expected for the degree of hearing loss, complementing a patient's hearing difficulty (e.g., I can hear sound but can't understand speech, especially in noise). Also, a host of neurological, audiological, and clinical features and findings reveals a variety of causes, genotypes and phenotypes, comorbidities, and auditory consequences. The desynchrony created by auditory neuropathy impairs neural processing, thereby resulting in a series of perceptual disadvantages and compromiseand to various degrees, disabling communication and auditory scene analysis. Whether occuring from a peripheral or a central site, the effects of temporal discord are universal: Auditory temporal processing determines our understanding of speech, our appreciation of music, being able to localize a sound source, and to listen to a person in a noisy crowd.2

Auditory system delineating the inner hair cells (sensory), pre- and postsynaptic portions (synapse), and the spiral ganglion and auditory nerve (neural). Cochlear implantation bypasses the sensory and synaptic portions providing a time-locked signal to the neural partition.6 Health loss, research, neuropathy.

Since the discovery of auditory neuropathy, researchers have described various sites of the lesion along the neural pathway. Auditory neuropathy is a condition of abnormal neural encoding of acoustic signals in the presence of normal sensory transduction and amplification properties of the outer hair cells.3 Potential disorders and sites of lesions include (1) presynaptic disorders affecting inner hair cells and ribbon synapses; (2) postsynaptic disorders affecting unmyelinated auditory nerve dendrites; (3) postsynaptic disorders affecting auditory ganglion cells and their myelinated axons and dendrites; and (4) central neural pathway disorders affecting the auditory brainstem.4 In some cases, auditory neuropathy may include brainstem connections such as those reported in individuals with multiple brainstem neuropathies.5 These structures are divided into three primary partitions responsible for encoding sound: sensory, synaptic, and neural (Fig. 1).6

Fortunately, advancements in auditory electrophysiology and psychophysical tests have made the identification of the site of lesion and functionality more available to clinical practice. These tools have greatly improved diagnosis, treatment selection, and outcome prediction. Having a basic understanding of this complex topic is useful for audiologists and ENT physicians because auditory neuropathy spectrum disorders (ANSDs) occur in children, adults, and seniors due to aging, noise exposure, trauma, and disease. Take note of these pearls of wisdom that will aid in evaluating, diagnosing, and discussing hearing loss and treatments with patients of all ages.

Research highlights relevant to audiology practices include notable information on ANSD prevalence, causations, symptoms, evaluation, testing, and treatments.

PREVALENCE. One in 7,000 neonates evaluated through newborn hearing screening has been found to have an abnormal auditory nerve function.4 ANSD is estimated to occur in one in 10 children with permanent hearing loss.7 Studies suggest that a considerable number of cases may occur in the well-baby population since newborn hearing screenings are typically based on otoacoustic emissions (OAEs)8 rather than auditory brainstem response (ABR)7 or simultaneous testing.

The incidence of patients with auditory neuropathy or cochlear synaptopathy9 in the general population is unknown. However, 10 percent of patients seen at Massachusetts Eye and Ear complain of hearing difficulty in the presence of clinically normal hearing,10 suggesting that ANSD and central auditory processing disorder (CAPD) evaluations should be considered for this population.

CAUSATION. Syndromic and nonsyndromic disorders cause auditory neuropathy through synaptic and neural pathways. Auditory neuropathy varies by etiology, onset age, site of lesion, auditory behavior, and the presence or absence of other peripheral neuropathies.11 Prematurity, low birth weight, hyperbilirubinemia, anoxia, otoferlin gene mutations, Waardenburg's syndrome, Charcot-Marie-Tooth disease (hereditary motor and sensory neuropathy), ototoxic drugs, infection, and cranial nerve hypoplasia, among others, have been reported as risk factors. Genetic disorders account for most cases, especially in children. A mild head injury can cause cranial nerve injury, including an injury to the eighth nerve, although this is less frequent.12

Auditory synaptopathy impairs sound encoding at the synapses between inner hair cells and spiral ganglion neurons.3 Should discrimination difficulty accompany normal hearing sensitivity by standard audiometry (some with ultra-high-frequency hearing loss) and a history of noise exposure or advanced aging, the patient may have cochlear synaptopathy or hidden hearing loss.13

SYMPTOM. Psychophysical testing reveals auditory neuropathy results in perceptual consequences that impair speech discrimination and auditory scene analysis. Unlike cochlear impairments, this condition has a minor effect on loudness, high-frequency pitch discrimination, or localization based on level differences. On the other hand, auditory neuropathy patients have deficiencies in time-based perceptions such as pitch discrimination at low frequencies, temporal integration and modulation detection, binaural beats, masking paradigms, hearing signals in noise, gap detection, and localization using interaural timing.14

Children with this condition may have excellent visual cognition but exhibit poor auditory skills.15 Speech may develop normally or be delayed. Speech discrimination may range from no difficulty in quiet with issues hearing in noise to profound hearing loss in quiet.7

Adults who acquire auditory neuropathy complain of difficulty understanding speech and deafness in background noise. They have difficulty with music perception, sound fading, and localization, and often dislike noise. They may be unemployable for certain jobs, cannot hear well on the telephone, and prefer online jobs and email for communication.

Patients with auditory neuropathy may have constant low-frequency bilateral tinnitus (< 1,000 Hz) with pitch matching at the greatest degree of hearing loss, typically 10 to 15 dB SL.16

In cases of comorbid peripheral neuropathy or a diagnosis of Charcot-Marie-Tooth disease (the most common inherited neurological disease), hearing loss occurs several years before the onset of other symptoms.3

Auditory neuropathy may be progressive as a result of several conditions. These include genetic mutations, mitochondrial disorders, autoimmune anomalies, degenerative changes from aging and noise trauma, toxic metabolic disorders, and nutritional deficits.3

Mutations of the OTOF gene (otoferlin) can express as a transient temperature-sensitive auditory neuropathy, which resolves once the increased body temperature is resolved.17,18 A gene responsible for autosomal dominant auditory neuropathy (AUNA1) was found in a family of European ancestry. The average age of symptom onset was 19 years old.19

EVALUATION. Audiological testing may cover a wide variety of evaluations depending on the patient's age. These may include testing of pure tones, hearing in noise, otoacoustic emissions with and without crossed suppression, acoustic reflexes, cochlear microphonics, summating potentials, ABR, and cortical auditory-evoked potential (CAEP), as well as tympanometry and electrocochleography (ECochG).

Medical evaluation includes an MRI of the inner ears, retrocochlear and brainstem structures, a complete history and genetic analysis, and a physical examination. Audiometric configurations can be downsloping, flat, or high frequency. Low-frequency or reverse curve loss is more prominent, potentially as a result of phase-locking difficulty caused by desynchrony compared to higher frequencies at approximately 2,000 Hz.1

In some cases of auditory neuropathy, patients may have abnormalities in the cochlear microphonic, low amplitude wave V without a wave I, and absent TEOAEs.20 Despite compromised ABRs, CAEPs can often be recorded in ANSD patients. Emerging research highlights the application of CAEP in estimating the behavioral thresholds in this population.21 A slower time constant and recovery allow for better synchrony and reliability.

Vestibular neuropathy may accompany findings of auditory and peripheral neuropathies. Some patients with abnormal caloric responses may be asymptomatic in the presence of peripheral neuropathy.22 The prevalence of at least one vestibular complaint with auditory neuropathy is 20 percent.23 Using the Dizziness Handicap Inventory, the severity of balance complaints is reported as moderate.24

The British Society of Audiology has published comprehensive recommendations for testing young infants who fail newborn screening or considered at risk for ANSD. Testing for this cohort starts with a 4kHz tpABR, followed by another test to identify sensorineural or mixed hearing loss or ANSD, such as a bone conduction ABR, 1 kHz or 0.5 kHz ABR, click ABR, OAE, and/or cochlear microphonics, tympanometry, or stapedial reflexes testing.7 In premature babies, ABR retesting over weeks and months should be conducted to identify those with delayed maturation.

TREATMENT. Goals for newborns with suspected ANSD are to provide appropriate treatment and begin rehabilitation within the first six months. Visual cueing is important in the early stages until the infant's hearing level and diagnosis can be established. Hearing aids, cochlear implants (CI), and rehabilitation options are guided by the locus of the lesion, the severity of synaptic degeneration, concomitant sensory loss, neural competency, and behavioral responses.

Hearing aids are not effective in many cases, although some studies suggest that a trial with amplification, which may include wireless communication, may be recommended based on the patient's degree of hearing loss, age, comorbidities, and behavioral factors. Amplification is typically fit to standard formulas. Enhanced spectral cues and low-pass filtering in the hearing aid prescription are suggested in some cases.7

Regarding CIs, assessment of spiral ganglion health using intraoperative ECochG measurements has become one of the best predictors of CI outcomes. Cochlear implantation results are better when the site of lesion is sensory or synaptic since the CI bypasses these regions to simulate the neural partition (Fig. 1).6 A new hypothesis suggests that binaural cues improve perception in noise. Screening for residual binaural sensitivity might be important when evaluating a patient with AN's candidacy for hearing aids and/or cochlear implants.25

Based on CAEP testing, children more likely show maturation effects within six months and age-appropriate responses when CIs are fitted under the age of two.26

Thoughts on something you read here? Write to us at HJ@wolterskluwer.com

Abdala C, Sininger YS, Starr A (2000). Distortion product otoacoustic emission suppression in subjects with auditory neuropathy, Ear Hear, Dec; 21(6), 542-553. DOI:10.1097/00003446-200012000-00002

CDC (2017). Hearing loss in children; 2017 Hearing Screening Summary. Retrieved online. https://www.cdc.gov/ncbddd/hearingloss/2017-data/01-data-summary.html

Jutras B, Russell LJ, Hurteau AM, Chapdelaine M (2003). Auditory neuropathy in siblings with Waardenburg's syndrome, Int J Ped Otorhinolaryngol, Oct; 67(10), 1133-1142. DOI: 10.1016/s0165-5876(03)00200-3

More:
Updates on Auditory Neuropathy Spectrum Disorder : The Hearing Journal - LWW Journals

COVID-19 Impact on Peripheral Neuropathy Treatment Market, Global Research Reports 2020-2021

In 2019, the global COVID-19 Impact on Peripheral Neuropathy Treatment Market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026.

COVID-19 Impact on Peripheral Neuropathy Treatment Market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global COVID-19 Impact on Peripheral Neuropathy Treatment Market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.The Report scope furnishes with vital statistics about the current market status and manufacturers. It analyzes the in-depth business by considering different aspects, direction for companies, and strategy in the industry.

After analyzing the report and all the aspects of the new investment projects, it is assessed the overall research and closure offered. The analysis of each segment in-detailed with various point views; that include the availability of data, facts, and figures, past performance, trends, and way of approaching in the market. The COVID-19 Impact on Peripheral Neuropathy Treatment Market report also covers the in-depth analysis of the market dynamics, price, and forecast parameters which also include the demand, profit margin, supply and cost for the industry.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the COVID-19 Impact on Peripheral Neuropathy Treatment Market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

In-depth analysis of expansion and growth strategies obtained by Key players and their effect on competition market growth. The research report also provides precise information on your competitors and their planning. All of the above will help you to make a clear plan for top-line growth.

Get sample copy of thisreport @ https://www.lexisbusinessinsights.com/request-sample-133713

Top key players @ Major competitors identified in this market include Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Aptinyx, Regenacy Pharmaceuticals, TEVA Pharmaceutical Industries, Immune Pharmaceuticals, etc.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of COVID-19 Impact on Peripheral Neuropathy Treatment Market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global COVID-19 Impact on Peripheral Neuropathy Treatment Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they COVID-19 Impact on Peripheral Neuropathy Treatment Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the key market trends impacting the growth of the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the challenges to market growth?

Who are the key vendors in the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

What are the market opportunities and threats faced by the vendors in the Global COVID-19 Impact on Peripheral Neuropathy Treatment Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia COVID-19 Impact on Peripheral Neuropathy Treatment Market;

3.) The North American COVID-19 Impact on Peripheral Neuropathy Treatment Market;

4.) The European COVID-19 Impact on Peripheral Neuropathy Treatment Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

COVID-19 Impact on Peripheral Neuropathy Treatment Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Complete Brochure @https://www.lexisbusinessinsights.com/request-sample-133713

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Business Development Manager)

US: +1 210 907 4145

APAC: +91 9867799788

6851 N Loop

1604 W San Antonio,

TX 78249

[emailprotected]

http://www.lexisbusinessinsights.com

Go here to read the rest:
COVID-19 Impact on Peripheral Neuropathy Treatment Market to Witness a Pronounce Growth During 2020-2025, Top key players are Eli Lilly, Johnson &...

DOYLESTOWN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (Kannalife or the Company) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that it has appointed biotechnology and pharmaceutical industry veteran, Terrence O. Tormey, to the Companys Board of Advisors.

Mr. Tormeys most recent position was CEO of Kibow Biotech, a company involved in the development of novel renal care treatment for chronic kidney disease. For over four decades, Mr. Tormey has held numerous C-Level management positions, board seats, and has led successful sales and marketing campaigns with well-known life sciences companies including Wyeth, OMAX Health, Prevention Pharmaceuticals, and McNeil CPC (Johnson & Johnson).

"Its really great to have Terry join our corporate advisory board and team of experts at Kannalife. His experience, vision and extraordinary body of knowledge in the life sciences industry come at a perfect time for us as we start to design our commercialization and distribution plan for Atopidine, said Dean Petkanas, CEO of Kannalife.

I am honored to serve as an advisor to Kannalife. They have remarkable scientists behind the entities in development. These scientists are addressing a most challenging unmet medical need that is pain relief without opioids. Specifically, a treatment for Chemotherapy Induced Peripheral Neuropathy (CIPN), which, when approved, will help improve the lives of hundreds of thousands of patients, Tormey said.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

Atopidine is Kannalifes novel, patented small molecule that has been shown to have protective and anti-inflammatory properties in pre-clinical testing. The same studies show that it has also outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation, including cytokines, TNF-a, IL-1b, and IL-6.

KLS-13019 is Kannalifes leading patented, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). Neither KLS-13019 or Atopidine have been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Their safety and efficacy have not been confirmed by FDA-approved research.

The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations:Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Investor Relations: Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

View post:
Kannalife, Inc. Appoints Terrence O. Tormey to the Company's Board of Advisors - GlobeNewswire